𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures

✍ Scribed by Curry, Edward WJ; Stronach, Euan A; Rama, Nona R; Wang, Yuepeng YP; Gabra, Hani; El-Bahrawy, Mona A

Book ID
121871583
Publisher
Nature Publishing Group
Year
2013
Tongue
English
Weight
424 KB
Volume
27
Category
Article
ISSN
0893-3952

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Expression of human telomerase subunits
Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors
✍ Satoru Kyo,; Taro Kanaya; Masahiro Takakura; Masaaki Tanaka; Atsuko Yamashita; H πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 105 KB πŸ‘ 2 views

Telomerase activity is involved in the maintenance of telomere length and is thought to be required for cellular immortality and oncogenesis. Three major subunits composing telomerase, human telomerase RNA (hTR), telomeraseassociated protein (TP1) and human telomerase catalytic subunit (hTERT), have

Enhancement of tumor-associated glycopro
Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors
✍ Helen E. Cajigas; Robert E. Scully; Ann D. Thor; Enrique Fariza πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 707 KB

The immunoreactivity of monoclonal antibody (MoAb) B72.3 with ovarian serous tumors of borderline malignancy from 44 women who were pregnant, were on hormone medication containing a progestin, or were known to be in the secretory phase of the menstrual cycle, was compared with that of similar tumors

Expression of urokinase-type plasminogen
Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
✍ Maria E. L. van der Burg; Sonja C. Henzen-Logmans; Els M. J. J. Berns; Wim L. J. πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 620 KB

Elevated levels of expression of the urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 have shown to be related to poor prognosis in a variety of cancer types. In the present study, cytosolic levels of uPA and PAI-1 were determined with enzyme-linked immunosorbent assays in cytosols